Show simple item record

dc.contributor.authorChandrasekar, Viveksandeep Thoguluva et al.
dc.description.abstractTreatment options for Severe acute respiratory syndrome‐related coronavirus‐2 (SARS‐CoV‐2) are limited with no clarity on efficacy and safety profiles. We performed a systematic review and meta‐analysis of studies on patients ≥ 18 years reporting data on therapeutic interventions in SARS‐CoV‐2. Primary outcome was all‐cause mortality and secondary outcomes were rates of mechanical ventilation, viral clearance, adverse events, discharge and progression to severe disease. Pooled rates and odds ratios (OR) were calculated. Twenty‐nine studies with 5207 patients were included. Pooled all‐cause mortality in intervention arm was 12.8% (95%CI: 8.1%‐17.4%). Mortality was significantly higher for studies using hydroxychloroquine (HCQ) for intervention (OR: 1.36, 95% CI: 0.97‐1.89). Adverse events were also higher in HCQ sub‐group (OR: 3.88, 95% CI: 1.60 – 9.45). There was no difference in other secondary outcomes. There is a need for well‐designed randomized clinical trials for further investigation of every therapeutic intervention for further insight into different therapeutic options.en_US
dc.subjectCoronavirus Infectionsen_US
dc.subjectInfectious Diseasesen_US
dc.titleSystematic Review and Meta‐analysis of Effectiveness of Treatment Options Against SARS‐CoV‐2 infectionen_US
eihealth.categoryInfection prevention and control, including health care workers protectionen_US
eihealth.categoryCandidate therapeutics RDen_US
eihealth.typePublished Articleen_US
eihealth.maincategorySave Lives / Salvar Vidasen_US
dc.relation.ispartofjournalJournal of Medical Virologyen_US

Files in this item


There are no files associated with this item.

This item appears in the following Collection(s)

Show simple item record